Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04065-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Valentine De Castro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France. Hauptthemen laut MEDLINE: Receptors, Aryl Hydrocarbon, T-Lymphocytes, Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ligue Contre le Cancer, BioImp project.
Abstract (Originalsprache)
The efficacy of T-cell-based cancer therapies can be limited by the tumor microenvironment which can lead to T cell dysfunction. Multiple studies, particularly in murine models, have demonstrated the capacity of the aryl hydrocarbon receptor (AHR) to negatively regulate antitumor T cell functions. AHR is a cytoplasmic receptor and transcription factor that was originally identified as a xenobiotic sensor, but has since been shown to play a significant role in the gene regulation of various immune cells, including T cells. Given the insights from murine studies, AHR emerges as a promising candidate to invalidate for optimizing T cell-based cancer therapies. However, the controversial role of AHR in human T cells underscores the need for a more comprehensive characterization of AHR expressing T cells. This study aims to investigate the regulatory mechanisms of AHR in human T cell biology to better understand its impact on reducing antitumor immune responses. Here, we knocked-out AHR in human T cells using CRISPR-Cas9 technology to characterize AHR's function in an in vitro chronic stimulation model. Engineered T cells exhibited enhanced effector- and memory-like profiles and expressed reduced amount of CD39 and TIGIT. AHR knockout enhanced human CAR-T cells' functionality and persistence upon tumor chronic stimulation. Collectively, these results highlight the role of AHR in human CAR-T cells efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France.
- MGX-Montpellier GenomiX, Université de Montpellier, CNRS, INSERM, Montpellier, France.
- Service d'hématologie et d'immunologie cellulaire, Centre Hospitalier Universitaire de Besançon, Besançon, France.
- Service d'oncologie médicale, Centre Hospitalier Universitaire de Besançon, Besançon, France.
- Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, 25000, Besançon, France. yann.godet@univ-fcomte.fr.
Förderung
- Ligue Contre le Cancer
- BioImp project
Zitieren
APA
De Castro, V., Abdellaoui, O., Dehecq, B., Ndao, B., Mercier-Letondal, P., Dauvé, A., Garnache-Ottou, F., Adotévi, O., Loyon, R., & Godet, Y. (2025). Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04065-5
Vancouver
De Castro V, Abdellaoui O, Dehecq B, Ndao B, Mercier-Letondal P, Dauvé A, et al. Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04065-5
BibTeX
@article{DeCastro2025,
author = {De Castro, Valentine and Abdellaoui, Oumaïma and Dehecq, Barbara and Ndao, Babacar and Mercier-Letondal, Patricia and Dauvé, Alexandra and Garnache-Ottou, Francine and Adotévi, Olivier and Loyon, Romain and Godet, Yann},
title = {Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04065-5}
}
EUVIMED